Reference Publications

AE1/AE3

Calponin

CD20

CD45

CEA

CK5

CK7

CK8/18

EMA

GFAP

Ki67

MART-1

Pan-CK 4Abs

Podoplanin

SMMS-1

Vimentin

1. Kiernan JA. Histological and Histochemical Methods: Theory and Practice. New York: Pergamon Press 1981.
2. Sheehan DC and Hrapchak BB. Theory and Practice of Histotechnology. St. Louis: C.V. Mosby Co. 1980.
3. Nadji M, Morales AR. Immunoperoxidase, part I: the techniques and its pitfalls. Lab Med. 1983; 14:767-771.

1. Woodcock-Mitchell J, Eichner R, et al. Immunolocalization of Keratin Polypeptides in Human Epidermis Using Monoclonal Antibodies. The Journal of Cell Biology. November 1982; 95:580-588.
2. Weiss RA, Eichner R, et al. Monoclonal Antibody Analysis of Keratin Expression in Epidermal Diseases: A 48- and 56-kdalton Keratin as Molecular Markers for Hyperproliferative Keratinocytes. The Journal of Cell Biology. April 1984; 98:1397-1406.
3. Moll R, Divo M, et al. The human keratins: biology and pathology. Histochem Cell Biol. 2008; 129:705–733.

1. Gusev NB. Some properties of caldesmon and calponin and the participation of these proteins in regulation of smooth muscle contraction and cytoskeleton formation. Biochemistry (Mosc). 2001 Oct; 66(10):1112-21.
2. Douglas-Jones A et al. Observer variability in the histopathological reporting of core biopsies of papillary breast lesions is reduced by the use of immunohistochemistry for CK5/6, calponin and p63. Histopathology 2005, 47, 202-08.
3. Abdallah DM and El Deeb NMF. Comparative Immunohistochemical Study of P63, SMA, CD10 and Calponin in Distinguishing In Situ from Invasive Breast Carcinoma. J Mol Biomark Diagn. 2017, 8(4), 1000342.
4. Perez-Montiel MD et al. Differential Expression of Smooth Muscle Myosin, Smooth Muscle Actin, H-Caldesmon, and Calponin in the Diagnosis of Myofibroblastic and Smooth Muscle Lesions of Skin and Soft Tissue. Am J Dermatopathol. 2006 Apr;28(2):105-11.

1. Chang KL, Arber DA, Weiss LM. CD20: A review. Applied Immunohistochemistry 1996; 4:1-15.
2. Jaffe ES, et al. WHO Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, IARC Press 2001.
3. Jilani I, et al. Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia. Blood. 2003 Nov; 102(10):3514-20.
4. Khalidi HS, et al. The immunophenotype of blast transformation of chronic myelogenous leukemia: a high frequency of mixed lineage phenotype in “Lymphoid” blasts and A comparison of morphologic, immunophenotypic, and molecular findings. Mod Pathol. 1998 Dec; 12:1211-21.

1. Krishna M. Diagnosis of Metastatic Neoplasms. Arch Pathol Lab Med. 2010; 134:207–215.
2. Andres TL, Kadin ME. Immunologic Markers in the Differential Diagnosis of Small Round Cell Tumors from Lymphocytic Lymphoma and Leukemia. Am J Clin Pathol 1983; 79:546-552.
3. Thunnissen E, Flieder DB, et al. The Use of Immunohistochemistry Improves the Diagnosis of Small Cell Lung Cancer and Its Differential Diagnosis. An International Reproducibility Study in a Demanding Set of Cases. Journal of Thoracic Oncology. 2017; Vol. 12 No. 2: 334-346. 

1. Berretta M, Alessandrini L, et al. Serum and tissue markers in colorectal cancer: State of art. Critical Reviews in Oncology/Hematology. 2017; 111:103–116.
2. Tiernan JP, Perry SL, et al. Carcinoembryonic antigen is the preferred biomarker for in vivo colorectal cancer targeting. Br J Cancer. 2013 Feb 19; 108 (3):662–667.
3. Wu K-L, Huang E-Y, et al. Synergistic interaction between galectin-3 and carcinoembryonic antigen promotes colorectal cancer metastasis. Oncotarget. 2017; Vol. 8, No. 37: 61935-61943.

1. Moll R, et al. Expression of keratin 5 as a distinctive feature of epithelial and biphasic mesotheliomas. An immunohistochemical study using monoclonal antibody. Virchows Arch B Cell Pathol. 1989; 58:129-45.
2. Ordonez NG. What are the current best immunohistochemical markers for the diagnosis of epithelioid mesothelioma? A review and update. Human Pathology. 2007; 38:1–16.

1. Montezuma D, et al. A panel of four immunohistochemical markers (CK7, CK20, TTF-1, and p63) allows accurate diagnosis of primary and metastatic lung carcinoma on biopsy specimens. Virchows Arch. 2013 Dec; 463(6):749-54.
2. Shin JH, et al. CK7, CK20, CDX2 and MUC2 Immunohistochemical staining used to distinguish metastatic colorectal carcinoma involving ovary from primary ovarian mucinous adenocarcinoma. Jpn J Clin Oncol. 2010 Mar;40(3):208-13.
3. Lambaudie E, et al. Cytokeratin 7 as a predictive factor for response to concomitant radiochemotherapy for locally advanced cervical cancer: a preliminary study. Anticancer Res. 2014, Jan; 34(1): 177-81.

1. Cimpean AM et al. Relevance of the immunohistochemical expression of cytokeratin 8/18 for the diagnosis and classification of breast cancer. Romaniam Journal of Morphology and Embryology. 2008; 49(4):479-483.
2. Reisenblichler ES et al. The predicative ability of a CK5/p63/CK8/18 antibody cocktail in stratifying breast papillary lesions on needle biopsy. Am J Clin Pathol. 2013; 140:767-779.

1. Jerome Marson V et al. Expression of TTF-1 and cytokeratins in primary and secondary epithelial lung tumours: correlation with histological type and grade. Histopathology. 2004; 45(2): 125-34.
2. Stroescu C., et al. The diagnostic value of cytokeratins and carcinoembryonic antigen immunostaining in differentiating hepatocellular carcinomas from intrahepatic cholangiocarcinomas. J Gastrointesin Liver Dis., 2006;(1): 9-14.
3. Durnez A. et al. The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin. Histopathology. 2006; 49(2)L 138-5
4. Maki M et al. Expression of cytokeratin 1, 5, 14, 19 and transforming growth factors-beta1, beta2, beta3 in osteofibrous dysplasia and adamantinoma: A possible association of transforming growth factor-beta with basal cell phenotype promotion. Pathol Int. 2000; 50(10): 801-7.

1. Chu PG et al. Immunohistochemical staining in the diagnosis of pancreatobiliary and ampulla of Vater adenocarcinoma: application of CDX2, CK17, MUC1, and MUC2. Am J Surg Pathol. 2005; 29(3): 359-67.
2. McGregor DK et al. Reduced expression of cytokeratin 20 in colorectal carcinomas with high levels of microsatellite instability. Am J Surg Pathol. 2004; 28(6): 712-8.
3. Terracciano LM et al. Hepatoid adenocarcinoma with liver metastasis mimicking hepatocellular carcinoma: an immunohistochemical and molecular study of eight cases. Am J Surg Pathol. 2003; 27(10): 1302-12.

1. Nassar H. et al. Pathogenesis of invasive micropapillary carcinoma: role of MUC1 glycoprotein. Mod Pathol. 2004 Sep; 17(9):1045-50.
2. Acs G, et al. Invasive ductal carcinomas of the breast showing partial reversed cell polarity are associated with lymphatic tumor spread and may represent part of a spectrum of invasive micropapillary carcinoma. Am J Surg Pathol. 2010 Nov; 34(11):1637-46.
3. Mino-Kenudson M, et al. Mucin expression in reactive gastropathy: an immunohistochemical analysis. Arch Pathol Lab Med. 2007 Jan; 131(1):86-90.
4. Kadin ME, et al. Primary cutaneous ALCL with phosphorylated/activated cytoplasmic ALK and novel phenotype: EMA/MUC1+, cutaneous lymphocyte antigen negative. Am J Surg Pathol. 2008 Sep; 32(9):1421-6.
5. Kuan SF, et al. Differential expression of mucin genes in mammary and extramammary Paget’s disease. Am J Surg Pathol. 2001 Dec; 25(12):1469 77.

1. Eng LF et al. Glial Fibrillary Acid Protein: GFAP-Thirty-One Years (1969- 2000) Neurochemical Res. 2000, 25(9/10):1439-1451.
2. Jessen KR et al. Molecular identity, distribution and heterogeneity of glial fibrillary acidic protein: an immunoblotting and immunohistochemical study of Schwann cells, satellite cells, enteric glia and astrocytes. J Neurocytol. 1984 Apr; 13(2):187-200.
3. Roessmann U et al. Glial fibrillary acidic protein (GFAP) in ependymal cells during development: an immunocytochemical study. Brain Res. 1980; 200(1):13-21.
4. O’Callaghan JP and Sriram K. Glial fibrillary acidic protein and related glial proteins as biomarkers of neurotoxity. Expert Opin Drug Saf. 2005 May; 4(3): 433-442.

1. Goodson WH 3rd, et al. The functional relationship between in vivo bromodeoxyuridine labeling index and Ki67 proliferation index in human breast cancer. Breast Cancer Res Treat. 1998 May; 49(2): 155-164.
2. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown [review]. J Cell Physiol. 2000; 182:311-22.
3. Lohmann CM, et al. Expression of melanocyte differentiation antigens and ki-67 in nodal nevi and comparison of ki-67 expression with metastatic melanoma. Am J Surg Pathol. 2002 Oct; 26(10):1351-7.

1. Orchard GE. Melan A (Mart-1): a new monoclonal antibody for malignant melanoma diagnosis. Br J Bioed Sci 1998 Mar; 55(1): 9-9
2. Kageshita T et al. Differential expression of Mart-1 in primary and metastatic melanoma lesions. J Immunother. 1997; 20:460-5
3. Cheraghi N et al. Melanoma Treated With Mohs Micrographic Surgery Using a Novel-Modified 15-Minute MART-1 Immunostain: Discussion of Technique and Experience. Dermatol Surg 2020;00:1-3

1. Woodcock-Mitchell J, Eichner R, et al. Immunolocalization of Keratin Polypeptides in Human Epidermis Using Monoclonal Antibodies. The Journal of Cell Biology. November 1982; 95:580-588.
2. Weiss RA, Eichner R, et al. Monoclonal Antibody Analysis of Keratin Expression in Epidermal Diseases: A 48- and 56-kdalton Keratin as Molecular Markers for Hyperproliferative Keratinocytes. The Journal of Cell Biology. April 1984; 98:1397-1406.
3. Moll R, Divo M, et al. The human keratins: biology and pathology. Histochem Cell Biol. 2008; 129:705–733.
4. Ordonez NG. What are the current best immunohistochemical markers for the diagnosis of epithelioid mesothelioma? A review and update. Human Pathology. 2007; 38:1–16.

1. Ugorski M et al. Podoplanin – a small glycoprotein with many faces. Am J. Cancer Res. 2016;6(2):370-386.
2. Breiteneder-Geleff S et al. Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. Am J Pathol. 1999 Feb; 154(2):385-94.
3. Astarita JL et al. Podoplanin: emerging functions in development, the immune system, and cancer. Frontiers in Immunology. 2012 Sep; 283(3):1- 11.

1. Kalof AN et al. Immunostaining patterns of myoepithelial cells in breast lesions: a comparison of CD10 and smooth muscle myosin heavy chain. J Clin Pathol. 2004; 57: 625-629.
2. Hill CB, Yeh IT. Myoepithelial cell staining patterns of papillary breast lesions: from intraductal papillomas to invasive papillary carcinomas. AM J Clin Pathol. 2005 123(1) 36-44.

1. Azumi N, Battifora H. The distribution of vimentin and keratin in epithelial and nonepithelial neoplasms. A comprehensive immunohistochemical study on formalin and alcohol-fixed tumors.Am J Clin Pathol.1987; 88:286-96.
2. Khoury JD, et al. The utility of epithelial membrane antigen and vimentin in the diagnosis of chromophobe renal cell carcinoma.Ann Diagn Pathol.2002; 6(3):154-58.
3. Hermann H, Aebi U. Intermediate filaments and their associations: multitalented structural elements specifying cytoarchitecture and cytodynamics. Curr Opin Cell Biol. 2000; 12:79-90..
4. Niveditha SR, Bajaj P. Vimentin expression in breast carcinomas. Indian J Pathol Microbiol. 2003; 46(4):579-84..